Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI’s research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at more than 200 locations in 20+ states across the U.S. Learn more about our research offerings.
Remote Monitoring May Reduce Inpatient Admission Rates Among Patients Receiving CAR T-Cell Therapy
December 10th 2023Remote patient monitoring following CAR T-cell therapy may reduce costs while allowing nurses to maintain a close eye on patient parameters, although more research is needed to refine the process of alerting virtual nurses of potential issues.
Defining and Quantifying the Oncology Nurse Navigator Role
October 7th 2021Deidra Hamilton, MSN, RN, OCN, ONN-CG, recently presented on how cancer institutions can clearly define the role of a nurse navigator to prevent scope creep and use gap analysis and metrics to showcase the value of a navigator in their program.